GAITHERSBURG, MD--(Marketwire - Sep 28, 2012) - Cytomedix, Inc. (
The results from a prospective case series assessing the use of PRP injections in facial rejuvenation were presented by Reza Nassab, a registrar in plastic surgery at BUPA Cromwell Hospital-London, in a poster entitled "The Use of Platelet Rich Plasma (PRP) in Facial Rejuvenation: Patient Reported Outcomes."
The Angel Whole Blood Separation System is a blood processing device and disposable products used for the separation of whole blood into red cells, platelet poor plasma and PRP. The higher platelet concentration results in higher concentrations of numerous growth factors including platelet derived growth factor, fibroblast growth factor, epithelial growth factor, vascular endothelial growth factor and transforming growth factor.
In this study, autologous PRP prepared with the Angel System was injected into the 28 patients (mean age of 58.6 years) following application of a topical local anesthesia cream and involved multiple injections covering the facial treatment area then subsequent injection of small volumes of PRP in a sub-dermal plane. Study participants were asked to complete a questionnaire regarding their experience of changes, complications and satisfaction following PRP treatment.
The questionnaire results reported skin changes that included increased radiance (53.8%), followed by improved texture (50.0%), improved tone (34.6%) and reduction in fine lines (30.8%). Most patients reported these changes after three weeks of treatment. Reported side effects, which included bruising, swelling and discomfort, were minor and resolved within 72 hours in most patients. No major complications or side effects were found in this study population.
Nassab reported, "Our study has shown an overall patient reported satisfaction rate of 61.5% with the PRP treatment. The main reported benefits include skin changes such as improved radiance, texture, tone and reduction in fine lines. There is a delay in the onset of these changes of more than three weeks from initial treatment reported by our patients. Although some patients (69.2%) reported some minor side effects such as swelling and bruising following PRP treatment, these were mostly resolved within 72 hours."
"These positive data underscore the versatility of our autologous PRP to show clinical utility in a variety of indications. Facial rejuvenation is another area in which our highly concentrated growth factors have potential regenerative benefit. We are encouraged by these findings and believe facial rejuvenation represents an attractive and significant private-pay opportunity for the Angel System," noted Martin Rosendale, Chief Executive Officer of Cytomedix.
Platelet-Rich Plasma (PRP) is a concentrated solution of the patient's platelets that may be applied to wounds or orthopedic sites to stimulate natural healing or as needed for clinical use requirements. PRP is produced from a small sample of the patients' blood using an advanced centrifuge that spins and separates blood components using precision separation technology (LED). Platelets are rich in growth factors that have regenerative capacity and stimulate healing. Platelets travel in blood and are generally the first to arrive at the site of injury. During the natural healing process, growth factors released from platelets help attract other repair cells, to allow normal healing to take place.
About Cytomedix, Inc.
Cytomedix, Inc. is a fully integrated regenerative medicine company commercializing and developing innovative platelet and adult stem cell separation products that enhance the body's natural healing processes. The Company's advanced autologous technologies offer clinicians a new treatment paradigm for wound and tissue repair. The Company's patient-derived PRP systems are marketed by Cytomedix in the U.S. and distributed internationally. Our commercial products include the AutoloGel™ System, cleared by the FDA for wound care and the Angel® Whole Blood Separation System. The Company is developing novel regenerative therapies using our proprietary ALDH Bright Cell ("ALDHbr") technology to isolate a unique, biologically active population of a patient's own stem cells. A Phase 2 trial evaluating the use of ALDHbr for the treatment of ischemic stroke is underway. For additional information please visit www.cytomedix.com.
Safe Harbor Statement
Statements contained in this press release not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix' actual results may differ materially due to a number of factors, many of which are beyond Cytomedix' ability to predict or control, including among many others, risks and uncertainties related to the Company's ability to successfully integrate the Aldagen acquisition, to successfully manage contemplated clinical trials, to manage and address the capital needs, human resource, management, compliance and other challenges of a larger, more complex and integrated business enterprise, viability and effectiveness of the Company's sales approach and overall marketing strategies, commercial success or acceptance by the medical community, competitive responses, the Company's ability to raise additional capital and to continue as a going concern, and Cytomedix's ability to execute on its strategy to market the AutoloGel™ System as contemplated. To the extent that any statements made here are not historical, these statements are essentially forward-looking. The Company uses words and phrases such as "believes", "forecasted," "projects," "is expected," "remain confident," "will" and/or similar expressions to identify forward-looking statements in this press release. Undue reliance should not be placed on forward-looking information. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. Additional risks that could affect our future operating results are more fully described in our U.S. Securities and Exchange Commission filings, including our Annual Report for the year ended December 31, 2011 and other subsequent filings. These filings are available at www.sec.gov.